
|Articles|July 1, 2006
Immune response modifier post-op
San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Harrison Nguyen, MD, MBA, MPH’s Deep Dive into CSU, Vasculitis, and Autoimmune Blisters
2
Day 3 Recap: SDPA Fall 2025
3
From TikTok to Targeted Therapy: Shannon Trotter, DO, on Modern Dermatology Challenges
4
Derm Dispatch at SDPA Fall 2025: How a New Initiative Will Transform Dermatologic Health Through Nutrition
5



















